NuvaRing® Injury Lawyers
NuvaRing® (ethinyl estradiol / etonogestrel) is the trade name for a vaginal contraceptive ring manufactured by Merck (formerly Schering-Plough, formerly Organon). Like other forms of combination hormonal contraception, NuvaRing contains estrogen and progestin hormones. However, the type of progestin used in the NuvaRing, is considered a third-generation progestin and is associated with a greater risk for developing blood clots than the type of progestin that is used in most birth control pills.
Thousands of lawsuits were filed on behalf of NuvaRing victims. Schlichter Bogard & Denton attorneys Roger Denton and Kristine Kraft were appointed as lead counsel by Judge Rodney Sippel of the Eastern District of Missouri in the multi-district litigation known as the In Re: NuvaRing Products Liability Litigation, MDL Docket No. 1964.
Roger Denton and Kristine Kraft were also appointed by the court to serve on the Plaintiffs’ Negotiating Committee and successfully negotiated a $100 million settlement on behalf of nearly all of the plaintiffs with qualifying claims.
Adverse Events Reported to FDA
Since NuvaRing became available in 2001, the U.S. Food and Drug Administration (FDA) received many reports of adverse events associated with the use of the NuvaRing. The most dangerous side effect is blood clotting, which can lead to a heart attack, stroke, or even death.
Some of the adverse events reported to the FDA included:
- Blood clots in legs or arms (deep vein thrombosis/DVT)
- Blood clots in the lungs (pulmonary embolism/PE)
- Ischemic stroke
- Heart attack
Schlichter Bogard & Denton is no longer accepting NuvaRing cases and therefore, the information on this page is provided for informational purposes.